MRK ▼ -0.1% - Merck & Co., Inc. $MRK - Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) Merck received a positive Committee for Medicinal Products for Human Use (CHMP) opinion from European regulators for its combination therapy of KEYTRUDA and Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, a development that typically supports approval in the EU. Despite this favorable regulatory advancement, MRK shares declined 0.1% today, suggesting the market may have already priced in expectations for the combination or remained focused on other factors. 18-SEP-2026 07:03 AM ET